A new trading day began on Tuesday, with Janux Therapeutics Inc (NASDAQ: JANX) stock price down -3.81% from the previous day of trading, before settling in for the closing price of $43.54. JANX’s price has ranged from $7.79 to $71.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 32.66%. Meanwhile, its annual earnings per share averaged -7.51%. With a float of $47.81 million, this company’s outstanding shares have now reached $52.34 million.
Considering the fact that the conglomerate employs 64 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 87.98%, operating margin of -658.76%, and the pretax margin is -463.91%.
Janux Therapeutics Inc (JANX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Janux Therapeutics Inc is 17.29%, while institutional ownership is 78.52%. The most recent insider transaction that took place on Jan 07 ’25, was worth 300,004. In this transaction President and CEO of this company sold 5,000 shares at a rate of $60.00, taking the stock ownership to the 293,054 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Officer proposed sale 5,000 for $60.00, making the entire transaction worth $300,004.
Janux Therapeutics Inc (JANX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -7.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -24.59% during the next five years compared to -92.62% drop over the previous five years of trading.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
Here are Janux Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 38.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 185.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.93 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Compared to the last year’s volume of 1.22 million, its volume of 1.22 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 46.91%. Additionally, its Average True Range was 3.69.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 7.88%, which indicates a significant decrease from 11.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.20% in the past 14 days, which was higher than the 89.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.93, while its 200-day Moving Average is $48.05. Nevertheless, the first resistance level for the watch stands at $43.17 in the near term. At $44.46, the stock is likely to face the second major resistance level. The third major resistance level sits at $45.12. If the price goes on to break the first support level at $41.22, it is likely to go to the next support level at $40.56. Should the price break the second support level, the third support level stands at $39.27.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
With a market capitalization of 2.42 billion, the company has a total of 52,482K Shares Outstanding. Currently, annual sales are 8,080 K while annual income is -58,290 K. The company’s previous quarter sales were 440 K while its latest quarter income was -28,060 K.
